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ABSTRACT
Introduction: Diabetes mellitus is a chronic
disease with a high prevalence world wide.
This disease has also been reported to affect
the quality of life (QOL) of the patient and their
family due to its chronic nature and multi organ
involvement. The aim of this study was to
analyze the association between adherence to
prescribed diabetes medication and
diabetes-specific QOL in patients attending
Secondary Health Care Facility in Bandung
City, Indonesia.
Methods: A cross-sectional survey was
conducted in the Secondary Health Care
Facility in Bandung City, Indonesia. Data were
collected between February and April 2014
using consecutive sampling. Adherence was
assessed using the eight-item Morisky
Medication Adherence Scale while
diabetes-specific-QOL was assessed using the
Diabetes 39 instrument.
Results: The results showed that among the
patients, 49.4% exhibited low adherence, 29.7%
exhibited medium adherence, and 20.9%
exhibited high adherence to diabetes
medication. Diabetes-specific QOL proved to
be highly affected in the sexual functioning
domain. Social-burden domain scores were
better than overall QOL scores. There was a
significant association between adherence and
diabetes-specific QOL (p = 0.009) using The
Kruskall-Wallis test of significance. The results
of the post hoc Mann–Whitney tests (high vs
medium adherence, p = 0.084; medium vs low
adherence, p = 0.86; and high vs low adherence,
p = 0.001) indicated that higher adherence to
prescribed diabetes medication contributed to
an improved QOL. Multiple regression analysis
showed that the predictors of diabetes-specific
QOL were adherence and patient income.
Conclusions: Adherence to prescribed
medication showed a positive effect on
diabetes-specific QOL in patients. Patients with
a high adherence to medication had an
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improved QOL. This result is important not
only in developing intervention programs for
patients but also in improving their QOL
through sustainable health promotion.
Keywords: Adherence; Diabetes-specific
quality of life; QOL; Prescribed medications;
Type 2; Diabetes mellitus
INTRODUCTION
Diabetes mellitus is a chronic disease with a
high prevalence world wide due to changing
lifestyles resulting in less physical activity and
increased obesity [1, 2]. The prevalence of this
disease is predicted to increase by 69% in
developing countries between 2010 and 2030
[1]. Treatment regimens for type 2 diabetes
mellitus (T2DM) require lifestyle and behavioral
changes and may influence daily functioning
and well-being in patients. This disease has also
been reported to affect the quality of life (QOL)
of the patient and their family due to its chronic
nature and multi organ involvement. Disease
severity has been found to be associated with
lower QOL [3]. Meanwhile, the majority of the
success of long-term maintenance therapy and
metabolic control in patients depends on their
adherence to medication and lifestyle changes.
The clinical impact of drug therapies for
diabetes has been restricted by low adherence
rates [4]. The World Health Organization
(WHO) has reported that the adherence rate in
patients on long-term therapy for chronic
diseases in developed countries is only 50%,
and adherence has been reported to be even
lower in developing countries [5]. Low
adherence to prescribed diabetes medication
leads to therapy failure and vital organ damage.
Thus, therapy failure has been associated with a
decrease in the benefits of therapy, leading to a
higher financial burden on the patients and
society at large [6].
A previous study comparing adherence
between insulin and oral medication groups
revealed that fewer patients in the insulin-only
group (20%) discontinued their treatment
compared with patients taking an oral
medication group (31%) [7]. On the other
hand, insulin therapy itself has been reported
to be associated with decreased QOL in diabetic
patients due to the pain associated with insulin
administration [8]. Moreover, it is known that
approximately 90% of diabetic patients have
T2DM [9, 10], whom in its early and middle
stage mostly still use oral medication therapy
and not insulin injection as may be required in
its late stage [11]. Therefore, this study solely
focused on adherence to oral medication
prescribed to T2DM patients.
A number of instruments are available for
measuring QOL in patients with diabetes,
including general instruments that are not
disease-specific, and also diabetes-specific
instruments. General instruments such as the
36-Item Short Form Health Survey and EuroQol
five dimensions questionnaire, have been
frequently used to assess QOL in patients with
different illnesses [12]. On the other hand,
diabetes-specific instruments specifically
measure the impact of diabetes on patient
functioning and well-being, and thus are more
sensitive for use in diabetic patients [3]. The
Diabetes 39 (D-39) Assessment Questionnaire
has been recognized to have reliable
psychometric properties and can be applied in
a wide variety of patients [13, 14]. Furthermore,
the D-39 is one of the various diabetes-specific
QOL measures that has proven to be responsive
to changes in patient health status [15].
Bandung City is the capital city for West Java
and the most populated province in Indonesia
(54.7% of Indonesian population lives in Java)
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[16]. Bandung City is also the second most
populated city in Indonesia after Surabaya. The
data analyzed in this study were obtained from
Secondary Health Care Facility, Bandung City,
Indonesia which is owned by the Bandung City
Government. Therefore, given its geographic
characteristics, we expected that Bandung City
would be representative of the general
Indonesian population, or at least the urban
population in Indonesia.
A recent systematic review identified several
disease-specific QOL indicators in patients with
diabetes [14]. Unfortunately, thus far, studies
examining the association between adherence
and diabetes specific-QOL in patients have been
inadequate. Thus, in this study, we explored the
association between adherence to oral diabetes
medication and disease-specific-QOL in T2DM
patients attending Secondary Health Care
Facility in Bandung City, Indonesia.
METHODS
Study Design
A cross-sectional survey was conducted from
February to April 2014 in Secondary Health
Care Facility, Bandung City, Indonesia.
Assuming a prevalence rate of 35% [17], a
minimum sample size of 91 was required to
obtain values with certainty at a 95%
confidence level. Thus, data were collected by
consecutive sampling who fit the following
inclusion criteria: confirmed diagnosis of
T2DM for over 3 months, prescribed only with
oral diabetes medication, not under insulin
injection therapy, more than 18 years old, and
attending Secondary Health Care Facility in
Bandung City, Indonesia.
All procedures performed in this study
involving human participants were in
accordance with the ethical standards of the
institutional and/or national research
committee and the 1964 Helsinki declaration
and its later amendments or comparable ethical
standards. Informed consent was obtained from
all patients after a full explanation of the
objective and procedures of the study. The
study protocol was approved by the Health
Research Ethics Committee of the Faculty of
Medicine, Universitas Padjadjaran No.
93/UN6.C2.1.2/KEPK/PN/2014.
Data Collection
Adherence was assessed using an eight-item
Morisky Medication Adherence Scale (MMAS)
[18]. The MMAS scale has been used for many
chronic diseases including diabetes, as a
self-reported measure of adherence to
prescribed medication and has been found to
have good reliability and predictive validity
[19]. All the questions were translated into the
Indonesian language and showed good validity
(r[0.3) and internal consistency, with a
Cronbach’s alpha of 0.724. Respondents were
classified as having low adherence if their score
was less than 6, medium adherence if their score
was 6 or 7, and high adherence if their score was
8.
Diabetes-specific-QOL was assessed using
the D-39. The D-39 instrument was selected
due to its applicability for use in the whole
T2DM patient population, as it is not specific
to demographic, gender, age, educational
level, health status, or ethnic groups. This
self-administered instrument allows patients
to describe how their QOL was affected during
the previous month in five dimensions
(domains): energy and mobility (15
questions), diabetes control (12 questions),
anxiety and worry (4 questions), social
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impact (5 questions), and sexual behavior (3
questions) [20]. To evaluate a multitude of
effects caused by diabetes illness and
treatments during the previous month,
patients were asked ‘‘How much was your
QOL affected’’. Responses were scored on a
seven-point scale that ranged from ‘‘not
affected at all’’ (score = 1) to ‘‘extremely
affected’’ (score = 7). The domain scores were
computed by summing the responses and
then applying a linear transformation to a
0–100 scale. Lower scores indicated a better
QOL. The instrument was translated and
validated in the Indonesian language and
demonstrated good internal consistency,
with a Cronbach’s alpha of 0.917.
Statistical Analysis
Descriptive statistics were used to investigate
the distribution of variables among T2DM
patients. Continuous variables were
represented using means, standard deviations,
medians, and interquartile ranges, whereas
categorical variables were represented using
counts and percentage. The Kruskall-Wallis
test of significance (p\0.05) was performed to
assess the association between adherence and
diabetes-specific QOL. A multiple regression
analysis (backward selection method) was used
to identify independent predictors of
diabetes-specific QOL. All statistical analyses
were carried out using SPSS software (version
17.0; IBM, Armonk, NY, USA).
RESULTS
Socio-Demographic Characteristics
A sample of 91 patients with T2DM were
included in this study. Table 1 shows the
socio-demographic and clinical characteristics
of these respondents. The average age of the
respondents was 61.1 ± 9.6 years, and 71% of
respondents were female. Most patients had
Table 1 Socio-demographic and clinical characteristics of












Level of last education
Elementary school 48 (42%)
Junior high school 22 (19%)









B5 years 50 (44%)
[5 years 64 (56%)








Kidney failure 6 (8%)
RMS regional minimum salary, IDR Indonesian Rupiah
a Regional Minimum Salary of Bandung City: IDR 1.538.703
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only graduated from elementary school (42%),
were not working/retired (86%), and had an
average monthly household income below the
regional minimum salary (72%). Most
respondents (56%) were diagnosed with
diabetes over 5 years prior to participation and
54% of the respondents had no family history of
having diabetes.
Adherence to Prescribed Diabetes
Medication
Self-reported adherence rates to prescribed
diabetes medication as measured by the
MMAS, indicated that 49.4% of patients had
low adherence, 29.7% of patients had medium
adherence, and 20.9% of patients had high
adherence.
Diabetes-Specific QOL in T2DM Patients
Figure 1 shows the mean scores for
diabetes-specific QOL. Social burden scores
(27.5) were lower than overall QOL scores
(39.1), while sexual functioning scores (52.8)
were higher than overall QOL scores (39.1).
Significant differences between the mean scores
for energy and mobility (45.4), diabetes control
(36.7), and anxiety and worry (29.8) were
identified.
Association Between Adherence
and Diabetes-Specific-QOL in Patients
There was a significant association between
adherence and diabetes specific-QOL, as
indicated by the Kruskall-Wallis test of
significance (p\0.05) (Table 2). Furthermore,
these results were analyzed using post hoc
Mann–Whitney tests. There was a significant
difference between patients with high and low
adherence in diabetes-specific QOL (p = 0.001).
Overall mean diabetes-specific QOL scores
were then plotted by level of adherence (low,
medium, and high adherence) (Fig. 2). These
results indicated that higher adherence to
medication contributed to improve
diabetes-specific QOL and vice versa. A lower
overall mean of diabetes-specific QOL score
indicated a better QOL.
Multiple regression analysis was used to
analyze the predictors of diabetes-specific
QOL. Adherence and income were found to be
significant predictors of diabetes-specific QOL
in patients (Table 3).
DISCUSSION
Poor adherence to medication and a lack of
understanding of medication instructions are
major barriers to the treatment of T2DM. Poor
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Fig. 1 Effect of medication adherence to diabetes-speciﬁc
QOL in T2DM patients
Table 2 Association between adherence and
diabetes-speciﬁc QOL in patients







QOL quality of life
* The Kruskall-Wallis test of signiﬁcance (p\0.05)
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recommendations may significantly contribute
to the economic burden of this disease. The rate
of high adherence identified in Bandung City
was 20.9%. This result was lower than that
reported in another study conducted in the
United States of America (79%) [21]. This
adherence rate was possibly associated with
the poor quality of pharmaceutical care
provided to patients. Pharmacists should
provide important information including what
to do if a dose is missed or an adverse effect is
caused by the prescribed medication. As
reported in our previous study, the average
dispensing time in community pharmacy in
Bandung City, Indonesia, was 62 s (varying
widely from 3 to 435 s), which is above the
recommended 60 s [22]. Therefore, pharmacists
should allocate more time for patient
consultation. In addition, another study
revealed that pharmaceutical care intervention
for diabetes treatment in Indonesia contributed
to improvements of 17.01%; 6.73%; and 6.31%
in 2 h postprandial glucose, HDL and
triglyceride parameters, respectively, relative to
treatment without the provision of
pharmaceutical care [23].
The primary objective of diabetes
management is to improve patient QOL. This
study established the association between
adherence and diabetes-specific QOL (and vice
versa). The D-39 diabetes specific-QOL
instrument has been suggested for use in
research and clinical practice [14].
Furthermore, this instrument not only reflects
the QOL in diabetes patients but also allows
patients to frame responses based on their own
personal conceptualization of QOL. These
properties result in an instrument that is
focused on the patients, which is important in
any patient-assessed QOL measure.
A number of previous studies have
attempted to analyze the association between
adherence and various diabetes specific-QOL
measures. However, within these studies,
associations have proven to be weak [24]. Only
a few domains have been analyzed [25], or only
type 1 diabetes was assessed [26]. Furthermore,
previous studies have focused on singular
aspects of QOL (e.g., distress [24]), and
neglected other key components of QOL, such
as physical and social functioning [13].
This study overcame the limitations of
previous studies and the results of this study
enhance the current body of evidence regarding
the positive association between adherence and
diabetes-specific-QOL in patients. The results of
Fig. 2 Higher patients adherence increase the dia-
betes-speciﬁc QOL. QOL quality of life
Table 3 Multiple regression models predicting
diabetes-speciﬁc QOL (N = 91)
Predictor variable B1 – SE B2 p value
Constant 60.348 ± 6.056 0.000
Adherence -3.325 ± 0.796 -0.291 0.004
Monthly income -6.780 ± 3.502 -0.193 0.050
B1 unstandardized sample regression co-efﬁcient, B2
standardized sample regression co-efﬁcient, Adjusted R2
13.4%, QOL quality of Life, SE standard error
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the Kruskall-Wallis test showed that adherence
to prescribed medication was significantly
associated with diabetes-specific-QOL and vice
versa (p = 0.009) in participating patients.
Furthermore, the multiple linear regression
model results suggested that adherence was
significantly associated with diabetes
specific-QOL. These results suggest that
increased occurence of high adherence to
diabetes-prescribed medicine was associated
with better QOL and vice versa. This result
also indicated the beneficial effects of the use of
anti-diabetic pharmacological therapies by
patients, which may have been associated with
decreased pain and other diabetes-related
complications.
The results of this study are in accordance
with those of Farias et al. [9], suggesting thatQOL
in patients with DM may influence treatment
adherence, satisfactorily improve clinical
outcomes and reduce morbidity and mortality
rates and disease progression. However, the
relationship between QOL and treatment
adherence remains contradictory. Some studies
[27, 28]have shown that thehighestQOL level in
patients with DM was associated with better
treatment adherence; however, other research
has not identified this association [29].
Based on our previous study, the predictors
of low adherence in Indonesia were
complementary and alternative medicine
usage [adjusted odds ratio (ORadj) 6.16;
2.44–15.52], gender (ORadj 2.57; 1.05–6.31),
and age (ORadj 4.25; 1.53–11.31) [30]. In
patients, adherence to medication may be
associated with relieved symptoms in the short
term and managed disease in the longer term,
thus resulting in better social functioning and
improved QOL. In contrast, a previous study by
Martinez [31] showed that there was no
association between medication adherence and
QOL measured by the World Health
Organization Quality of Life questionnaire
(WHOQOL-100) in T2DM patients. That study
recommended that it was necessary to
investigate psychological predictors of therapy
adherence behavior in T2DM patients. These
different findings may be a result of differences
in the instruments used, patients
socio-demographics and healthcare settings.
The results of the multiple regression
analysis also revealed that patient income was
significantly associated with diabetes-specific
QOL. As estimated, it was found that patients
with lower incomes had a significantly lower
QOL. This result is in agreement with prior
studies by Glasgow et al. [32] and Ferrans et al.
[33]. The decreased QOL in this population
showed the need to reform the treatment of
low-income diabetes patients.
Of all the diabetes-specific-QOL domain
scores, the social burden (27.5%) was lower
than the overall QOL score which indicated
better QOL. In the instrument used, lower score
is associated with better QOL. In contrast, a
previous study showed a substantial effect (50%
or more) of social functioning on QOL in
patients [34]. A probable explanation for this
difference is the presence of full support from
the patient’s family or social support from the
work environment. Social support could
encourage improved psychological conditions
and better adherence to prescribed diabetes
medication. Better family and social support
has been found to be predictive of higher
adherence and better QOL [35]. Further, all
the patients in this study were T2DM patients
who had experienced a lower level of impact on
their social life than that previously reported in
type 1 diabetes patients, in whom more social
control problems have been reported [36]. Thus,
it is possible that patients did not worry that
diabetes might limit their social relationships or
friendships.
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On the other hand, sexual functioning scores
were higher than overall QOL scores which
indicated poor QOL. In the instrument used,
higher score is associated with poor QOL. This
result is in accordance with a previous study
that reported the sexual dysfunctions associated
with diabetes have been known to decrease
QOL in both males and females [37]. Sexual
dysfunction has been frequently identified in
diabetes mellitus patients. The prevalence of
erectile dysfunction among diabetic men has
been estimated to be 35–90% [38]. The topic of
sexual activity is very sensitive to Indonesians
and not pleasant to talk about to the public. A
study of the help-seeking patterns (on the issues
of sexual behavior and dysfunction) in urban
populations in China, Taiwan, South Korea,
Japan, Thailand, Singapore, Malaysia, Indonesia
and the Philippines showed that although
sexual dysfunction was frequent, socio-cultural
factors seemed to prevent suffering individuals
from seeking treatment [39]. A self-reported
instrument is, however, still the best way to
investigate complicated information. Low
adherence to medications could have limited
the effects of medication on pain management
and sexual functioning. There were slight
differences between the mean scores in the
energy and mobility, diabetes control, and
anxiety and worry domains. However, these
domains were proven to not have an effect on
diabetes patients in this study.
In this study, we restricted to only T2DM
patients who used oral medication to prevent
any confounding associatedwith insulin use that
might affect adherence. We also stratified
predictors into categories to minimize
confounding and facilitate interpretation of the
data. However, this study still had several
limitations. First, the sample size of 91 patients
mayhave limited the power of the analyses, thus,
the generalizability of this study may also be
limited. Subsequent studies should not only use
larger and more diverse samples to ensure
sufficient power and generalizability but also
should use a case control study design with
groups defined according adherence to therapy.
In addition, other information that may
influence adherence should also be assessed,
such as the use of other medications and the
frequency of dosage, costs, and side effects of
medication. Second, our data relied on the
respondents’ self-reported data regarding their
medication adherence and may have been
subject to recall bias. This possibility, however,
should have been minimized as the MMAS has
been a validated and is a self-reported instrument
most widely used to assess adherence.
CONCLUSIONS
Adherence to prescribed medication was
positively associated with
diabetes-specific-QOL in patients. Patients with
high adherence also had a better QOL. This
result is useful not only in developing
intervention programs for patients but also in
improving their QOL through sustainable
health promotion.
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